<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018378</url>
  </required_header>
  <id_info>
    <org_study_id>HM-VANC-101</org_study_id>
    <nct_id>NCT04018378</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1502</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1502 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial aims to assess the pharmacokinetics, safety and tolerability of HIP1502 in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 6, 2017</start_date>
  <completion_date type="Actual">September 17, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>an open-label, randomized, single-dose crossover clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>0 (predose) ~ 96 hours</time_frame>
    <description>area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 (predose) ~ 96 hours</time_frame>
    <description>maximum plasma concentration of the drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0 (predose) ~ 96 hours</time_frame>
    <description>time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>0 (predose) ~ 96 hours</time_frame>
    <description>terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>0 (predose) ~ 96 hours</time_frame>
    <description>apparent total body clearance of the drug from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>0 (predose) ~ 96 hours</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: HGP1604 1mg (reference drug, R) will be administered once orally.
period 2: HIP1502 1mg (test drug, T) will be administered once orally after 14 days of the washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>period 1: HIP1502 1mg (test drug, T) will be administered once orally.
period 2: HGP1604 1mg (reference drug, R) will be administered once orally after 14 days of the washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT</intervention_name>
    <description>varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.</description>
    <arm_group_label>RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR</intervention_name>
    <description>varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.</description>
    <arm_group_label>TR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between ≥20 and ≤45 years old

          2. Weight ≥ 50 kg, with calculated body mass index (BMI) of ≥ 18 and ≤ 29.9 kg/m2

          3. Subject who voluntarily agrees to participate in this study and signs the informed
             consent form.

        Exclusion Criteria:

          1. History or presence of clinically significant and active cardiovascular, respiratory,
             hepatobiliary, renal, hematological, oncological, urinary, psychiatric,
             gastrointestinal, endocrine, immune, dermatologic or neurologic disorder.

          2. With symptoms indicating acute illness within 28 days prior to the first IP
             administration.

          3. Any medical history that may affect drug absorption, distribution, metabolism, and
             excretion.

          4. Any clinically significant activity of chronic medical illness.

          5. History of any clinically significant allergic reaction including induced by
             varenicline (However, mild allergic rhinitis or allergic dermatitis which do not
             require medication could be included).

          6. Positive blood tests for HBs Ag, anti-HCV Ab, anti-HIV Ab, or VDRL.

          7. Use of any prescription drugs and herbal preparations within 14 days prior to study
             drug administration or use of over-the-counter medications (OTC) and vitamin products
             within 10 days prior to study drug administration.

          8. Inability to take standard hospital diet.

          9. Donation of blood within 60 days prior to study drug administration or apheresis
             within 20 days, or blood transfusion within 30 days prior to the first IP
             administration.

         10. Exposure to any investigational drug or placebo within 90 days prior to the last IP
             administration.

         11. Subjects with excessive caffeine intake (more than 5 cups/day), heavy or regular
             alcohol intake (more than 210 g/week).

         12. Any use of tobacco or nicotine within three months.

         13. Subjects rejected to use clinically effective contraceptive methods during the study
             period.

         14. Subjects having been deemed inappropriate for the trial as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Clinical Pharmacology &amp; Toxicology, Anam Hospital, Korea University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Young Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

